192 related articles for article (PubMed ID: 10500832)
1. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.
Gorlick R; Cole P; Banerjee D; Longo G; Li WW; Hochhauser D; Bertino JR
Adv Exp Med Biol; 1999; 457():543-50. PubMed ID: 10500832
[TBL] [Abstract][Full Text] [Related]
2. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.
Rots MG; Pieters R; Peters GJ; Noordhuis P; van Zantwijk CH; Kaspers GJ; Hählen K; Creutzig U; Veerman AJ; Jansen G
Blood; 1999 Mar; 93(5):1677-83. PubMed ID: 10029597
[TBL] [Abstract][Full Text] [Related]
3. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression.
Gorlick R; Goker E; Trippett T; Steinherz P; Elisseyeff Y; Mazumdar M; Flintoff WF; Bertino JR
Blood; 1997 Feb; 89(3):1013-8. PubMed ID: 9028333
[TBL] [Abstract][Full Text] [Related]
4. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias.
Longo GS; Gorlick R; Tong WP; Lin S; Steinherz P; Bertino JR
Oncol Res; 1997; 9(5):259-63. PubMed ID: 9306433
[TBL] [Abstract][Full Text] [Related]
5. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method.
Rots MG; Willey JC; Jansen G; Van Zantwijk CH; Noordhuis P; DeMuth JP; Kuiper E; Veerman AJ; Pieters R; Peters GJ
Leukemia; 2000 Dec; 14(12):2166-75. PubMed ID: 11187907
[TBL] [Abstract][Full Text] [Related]
6. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.
Panetta JC; Yanishevski Y; Pui CH; Sandlund JT; Rubnitz J; Rivera GK; Ribeiro R; Evans WE; Relling MV
Cancer Chemother Pharmacol; 2002 Nov; 50(5):419-28. PubMed ID: 12439601
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia.
Rots MG; Pieters R; Peters GJ; Noordhuis P; Van Zantwijk CH; Henze G; Janka-Schaub GE; Veerman AJ; Jansen G
Br J Haematol; 2000 Jun; 109(3):629-34. PubMed ID: 10886214
[TBL] [Abstract][Full Text] [Related]
8. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
[TBL] [Abstract][Full Text] [Related]
9. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
[TBL] [Abstract][Full Text] [Related]
10. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells.
Longo GS; Gorlick R; Tong WP; Ercikan E; Bertino JR
Blood; 1997 Aug; 90(3):1241-5. PubMed ID: 9242558
[TBL] [Abstract][Full Text] [Related]
11. Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia.
Argiris A; Longo GS; Gorlick R; Tong W; Steinherz P; Bertino JR
Leukemia; 1997 Jun; 11(6):886-9. PubMed ID: 9177445
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Peters GJ; van Woerden NL; Dubbelman B; Escherich G; Schmiegelow K; Sonneveld E; Pieters R; van de Ven PM; Jansen G; Assaraf YG; Kaspers GJ; Cloos J
J Hematol Oncol; 2015 May; 8():61. PubMed ID: 26022503
[TBL] [Abstract][Full Text] [Related]
13. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
Levy AS; Sather HN; Steinherz PG; Sowers R; La M; Moscow JA; Gaynon PS; Uckun FM; Bertino JR; Gorlick R;
J Pediatr Hematol Oncol; 2003 Sep; 25(9):688-95. PubMed ID: 12972803
[TBL] [Abstract][Full Text] [Related]
14. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
Panetta JC; Sparreboom A; Pui CH; Relling MV; Evans WE
PLoS Comput Biol; 2010 Dec; 6(12):e1001019. PubMed ID: 21152005
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
16. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.
Trippett T; Schlemmer S; Elisseyeff Y; Goker E; Wachter M; Steinherz P; Tan C; Berman E; Wright JE; Rosowsky A
Blood; 1992 Sep; 80(5):1158-62. PubMed ID: 1381235
[TBL] [Abstract][Full Text] [Related]
17. Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.
Wojtuszkiewicz A; Raz S; Stark M; Assaraf YG; Jansen G; Peters GJ; Sonneveld E; Kaspers GJ; Cloos J
Int J Cancer; 2016 Apr; 138(7):1645-56. PubMed ID: 26547381
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.
Matherly LH; Taub JW
Leuk Lymphoma; 1996 May; 21(5-6):359-68. PubMed ID: 9172800
[TBL] [Abstract][Full Text] [Related]
19. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy.
Zhang L; Taub JW; Williamson M; Wong SC; Hukku B; Pullen J; Ravindranath Y; Matherly LH
Clin Cancer Res; 1998 Sep; 4(9):2169-77. PubMed ID: 9748136
[TBL] [Abstract][Full Text] [Related]
20. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
